AU6773200A - Egfh2 genes and gene products - Google Patents
Egfh2 genes and gene productsInfo
- Publication number
- AU6773200A AU6773200A AU67732/00A AU6773200A AU6773200A AU 6773200 A AU6773200 A AU 6773200A AU 67732/00 A AU67732/00 A AU 67732/00A AU 6773200 A AU6773200 A AU 6773200A AU 6773200 A AU6773200 A AU 6773200A
- Authority
- AU
- Australia
- Prior art keywords
- egfh2
- genes
- gene products
- gene
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14998699P | 1999-08-20 | 1999-08-20 | |
US60149986 | 1999-08-20 | ||
PCT/US2000/022326 WO2001014415A2 (en) | 1999-08-20 | 2000-08-15 | Egfh2 genes and gene products |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6773200A true AU6773200A (en) | 2001-03-19 |
Family
ID=22532642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU67732/00A Abandoned AU6773200A (en) | 1999-08-20 | 2000-08-15 | Egfh2 genes and gene products |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1208198A2 (en) |
JP (1) | JP2003510029A (en) |
AU (1) | AU6773200A (en) |
WO (1) | WO2001014415A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094882B2 (en) | 2000-04-21 | 2006-08-22 | Yeda Research And Development Co. Ltd. | Growth factor which acts through erb b-4 rtk |
US6544759B1 (en) | 2000-04-21 | 2003-04-08 | Yeda Research And Development Co. Ltd | Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
EP2976094B1 (en) * | 2013-03-21 | 2019-08-28 | The Regents of The University of Michigan | Methods of treating metabolic disorders |
AR121035A1 (en) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | NEUREGULIN-4 COMPOUNDS AND METHODS OF USE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121415A (en) * | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
-
2000
- 2000-08-15 EP EP00955542A patent/EP1208198A2/en not_active Withdrawn
- 2000-08-15 AU AU67732/00A patent/AU6773200A/en not_active Abandoned
- 2000-08-15 WO PCT/US2000/022326 patent/WO2001014415A2/en active Application Filing
- 2000-08-15 JP JP2001518744A patent/JP2003510029A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003510029A (en) | 2003-03-18 |
EP1208198A2 (en) | 2002-05-29 |
WO2001014415A2 (en) | 2001-03-01 |
WO2001014415A3 (en) | 2001-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6069300A (en) | Novel human genes and gene expression products | |
AU4053699A (en) | Novel human genes and gene expression products | |
AU4187499A (en) | Human genes and gene expression products v | |
AU2095599A (en) | Human genes and gene expression products i | |
AU2001285047A1 (en) | Human genes and gene expression products | |
AU2001245619A1 (en) | Human genes and gene expression products | |
AU2839401A (en) | Enzymes and genes used for producing vanillin | |
AU2088801A (en) | Metastasis genes and uses thereof | |
AU3072500A (en) | Rhamnosyl-transferase gene and uses thereof | |
AU2002327607A1 (en) | Human genes and gene expression products isolated from human prostate | |
AU1099701A (en) | Alpha1-3 galactosyltransferase gene and promoter | |
AUPQ262599A0 (en) | Gene expression | |
AU1101901A (en) | Human fgf-20 gene and gene expression products | |
AU2001226922A1 (en) | Cancer associated genes and their products | |
AU3133799A (en) | Seed-coat promoters, genes and gene products | |
AU6263999A (en) | Human genes and gene expression products | |
AU6773200A (en) | Egfh2 genes and gene products | |
EP1144631A3 (en) | Insulin-synthesis genes | |
AU2400401A (en) | Novel phosphodiesterases and genes thereof | |
AU3457899A (en) | Blk genes, gene products and uses thereof in apoptosis | |
AU2153401A (en) | Gene expression in biological conditions | |
AU1894601A (en) | Novel gene and use thereof | |
AU2002243300A1 (en) | Human genes and gene expression products isolated from human prostate | |
AU2001287269A1 (en) | Human genes and expression products | |
AU4237700A (en) | Genes and expression products from hematopoietic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |